{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:50:29Z","timestamp":1775004629404,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004006","name":"Istanbul University Scientific Research Projects Unit","doi-asserted-by":"publisher","award":["TSA-2017-25370"],"award-info":[{"award-number":["TSA-2017-25370"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Istanbul University Scientific Research Projects Unit","doi-asserted-by":"publisher","award":["TDK-2021-38358"],"award-info":[{"award-number":["TDK-2021-38358"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002657","name":"Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"Scientific and Technological Research Council of Turkey","doi-asserted-by":"publisher","award":["112S483"],"award-info":[{"award-number":["112S483"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neo.2025.101153","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:55:17Z","timestamp":1741924517000},"page":"101153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression"],"prefix":"10.1016","volume":"63","author":[{"given":"\u0130ldeniz","family":"USLU-BI\u00c7AK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meliha","family":"NAL\u00c7ACI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sel\u00e7uk","family":"S\u00d6ZER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.neo.2025.101153_bib0001","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.neo.2025.101153_bib0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clinic. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2025.101153_bib0003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"New England J. Med."},{"issue":"13","key":"10.1016\/j.neo.2025.101153_bib0005","first-page":"2176","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood, J. Am. Soc. Hematol.."},{"key":"10.1016\/j.neo.2025.101153_bib0006","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"2","key":"10.1016\/j.neo.2025.101153_bib0007","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2025.101153_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11899-013-0176-z","article-title":"Are MPNs vascular diseases?","volume":"8","author":"Finazzi","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"2","key":"10.1016\/j.neo.2025.101153_bib0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.hoc.2020.11.006","article-title":"Thrombotic, vascular, and bleeding complications of the myeloproliferative neoplasms","volume":"35","author":"Schafer","year":"2021","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.neo.2025.101153_bib0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev-immunol-020711-075008","article-title":"Cancer and inflammation: an old intuition with rapidly evolving new concepts","volume":"30","author":"Trinchieri","year":"2012","journal-title":"Annu. Rev. Immunol."},{"issue":"25","key":"10.1016\/j.neo.2025.101153_bib0011","first-page":"6515","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"2","key":"10.1016\/j.neo.2025.101153_bib0012","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1586\/17474086.2013.876356","article-title":"Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms","volume":"7","author":"Hasselbalch","year":"2014","journal-title":"Expert. Rev. Hematol."},{"issue":"7","key":"10.1016\/j.neo.2025.101153_bib0013","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.neo.2025.101153_bib0014","first-page":"305","article-title":"Can novel insights into the pathogenesis of myeloproliferative neoplasm-related thrombosis inform novel treatment approaches?","volume":"2","author":"Wolach","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.neo.2025.101153_bib0015","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood.V82.5.1532.1532","article-title":"Chromosomal assignment of the Human thrombin receptor gene: localization to region ql3 of chromosome 5","volume":"82","author":"Bahou","year":"1993","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.neo.2025.101153_bib0016","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1124\/pr.111.004747","article-title":"Cofactoring and dimerization of proteinase-activated receptors","volume":"65","author":"Lin","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neo.2025.101153_bib0017","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10555-015-9599-4","article-title":"Protease-activated receptors (PARs)\u2014Biology and role in cancer invasion and metastasis","volume":"34","author":"Wojtukiewicz","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.neo.2025.101153_bib0018","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00702-019-02075-z","article-title":"Role of the protease-activated receptor 1 in regulating the function of glial cells within central and peripheral nervous system","volume":"126","author":"Pompili","year":"2019","journal-title":"J. Neural Transm."},{"issue":"23","key":"10.1016\/j.neo.2025.101153_bib0019","first-page":"5037","article-title":"Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis","volume":"116","author":"McEachron","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"6","key":"10.1016\/j.neo.2025.101153_bib0020","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.neo.2025.101153_bib0021","doi-asserted-by":"crossref","first-page":"13146","DOI":"10.1016\/S0021-9258(18)42184-9","article-title":"Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function","volume":"267","author":"Scarborough","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.neo.2025.101153_bib0022","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1073\/pnas.96.20.11189","article-title":"Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity","volume":"96","author":"Andersen","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0023","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/1471-2407-10-443","article-title":"The activation of Proteinase-activated Receptor-1 (PAR1) mediates gastric cancer cell proliferation and invasion","volume":"10","author":"Fujimoto","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neo.2025.101153_bib0024","article-title":"Role of thrombin in angiogenesis and tumor progression","author":"Tsopanoglou","year":"2004","journal-title":"Semin. Thrombosis Hemostasis;"},{"issue":"11","key":"10.1016\/j.neo.2025.101153_bib0025","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/nm.3960","article-title":"PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells","volume":"21","author":"Gur-Cohen","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0026","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/nyas.13013","article-title":"Regulation of long-term repopulating hematopoietic stem cells by EPCR\/PAR1 signaling","volume":"1370","author":"Gur-Cohen","year":"2016","journal-title":"Ann. NY Acad. Sci."},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jth.14663","article-title":"Role of thrombomodulin expression on hematopoietic stem cells","volume":"18","author":"Basu","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.neo.2025.101153_bib0028","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41408-017-0010-2","article-title":"CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles","volume":"7","author":"Zini","year":"2017","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.neo.2025.101153_bib0029","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/ajh.22046","article-title":"Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera (vol 86, pg 337, 2011)","volume":"86","author":"Panova-Noeva","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.neo.2025.101153_bib0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0031","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2013.05.003","article-title":"ADP-induced platelet aggregation and thrombin generation are increased in Essential thrombocythemia and polycythemia Vera","volume":"132","author":"Panova-Noeva","year":"2013","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0032","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5507\/bp.2016.064","article-title":"Thrombin generation-a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms","volume":"161","author":"Mihaila","year":"2017","journal-title":"Biomed. Papers"},{"issue":"6","key":"10.1016\/j.neo.2025.101153_bib0033","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0960-894X(99)00101-8","article-title":"Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists","volume":"9","author":"Doller","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.neo.2025.101153_bib0034","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/ecp.12.19","article-title":"Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives","volume":"5","author":"Kalantzi","year":"2012","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.neo.2025.101153_bib0035","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0036","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4274\/tjh.galenos.2022.2022.0343","article-title":"Circulating CD133+\/\u2013CD34\u2013 Have increased c-MYC expression in myeloproliferative neoplasms","volume":"40","author":"\u0130","year":"2023","journal-title":"Turk. J. Haematol."},{"issue":"5","key":"10.1016\/j.neo.2025.101153_bib0037","first-page":"2667","article-title":"Activated protein C\u2013cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood","volume":"111","author":"Schuepbach","year":"2008","journal-title":"J. Am. Soc. Hematol."},{"issue":"4","key":"10.1016\/j.neo.2025.101153_bib0038","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5301\/JBM.2012.10437","article-title":"Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway","volume":"27","author":"Ohshiro","year":"2012","journal-title":"Int. J. Biol. Markers"},{"issue":"52","key":"10.1016\/j.neo.2025.101153_bib0039","doi-asserted-by":"crossref","first-page":"42887","DOI":"10.1074\/jbc.M505506200","article-title":"The tissue factor requirement in blood coagulation","volume":"280","author":"Orfeo","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1742-7843.2007.00078.x","article-title":"Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism","volume":"101","author":"Di Serio","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"68","key":"10.1016\/j.neo.2025.101153_bib0041","doi-asserted-by":"crossref","first-page":"43005","DOI":"10.1039\/C7RA07927C","article-title":"A label-free screening approach targeted protease-activated receptor 1 based on dynamic mass redistribution in living cells","volume":"7","author":"Tang","year":"2017","journal-title":"RSC Adv."},{"issue":"6","key":"10.1016\/j.neo.2025.101153_bib0042","first-page":"5291","article-title":"Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT\/JNK and NF\u2011\u03bab signaling pathways","volume":"19","author":"Pang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.neo.2025.101153_bib0043","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2016.04.008","article-title":"Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran","volume":"142","author":"Ellinghaus","year":"2016","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.neo.2025.101153_bib0044","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/ATVBAHA.117.309926","article-title":"Paradigm of biased PAR1 (Protease-Activated Receptor-1) activation and inhibition in endothelial cells dissected by phosphoproteomics","volume":"37","author":"van den Eshof","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.neo.2025.101153_bib0045","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bcmd.2009.08.005","article-title":"Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo","volume":"43","author":"Sozer","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.neo.2025.101153_bib0046","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"9","key":"10.1016\/j.neo.2025.101153_bib0047","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3390\/cells9092136","article-title":"Cytokine profiling in myeloproliferative neoplasms: overview on phenotype correlation, outcome prediction, and role of genetic variants","volume":"9","author":"Masselli","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.neo.2025.101153_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216810","article-title":"Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures","volume":"14","author":"Wong","year":"2019","journal-title":"PLoS. One"},{"issue":"2","key":"10.1016\/j.neo.2025.101153_bib0049","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.advms.2023.03.003","article-title":"Effect of hypoxia on HIF-1alpha and NOS3 expressions in CD34(+) cells of JAK2V617F-positive myeloproliferative neoplasms","volume":"68","author":"Soroglu","year":"2023","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.neo.2025.101153_bib0050","doi-asserted-by":"crossref","unstructured":"Falanga A., Marchetti M., editors. Thrombosis in myeloproliferative neoplasms. Seminars in thrombosis and hemostasis; 2014: Thieme Medical Publishers.","DOI":"10.1055\/s-0034-1370794"},{"issue":"2","key":"10.1016\/j.neo.2025.101153_bib0051","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1152\/physrev.00028.2003","article-title":"Protease-activated receptors: contribution to physiology and disease","volume":"84","author":"OSSOVSKAYA","year":"2004","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.neo.2025.101153_bib0052","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J. Thrombosis Haemostasis"},{"issue":"13","key":"10.1016\/j.neo.2025.101153_bib0053","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/bloodadvances.2021004360","article-title":"A thrombin-PAR1\/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C)","volume":"5","author":"Subramaniam","year":"2021","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.neo.2025.101153_bib0054","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1101\/gad.186411.111","article-title":"A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia","volume":"26","author":"Simon","year":"2012","journal-title":"Genes Dev."},{"issue":"1\u20132","key":"10.1016\/j.neo.2025.101153_bib0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutation Res."},{"issue":"6907","key":"10.1016\/j.neo.2025.101153_bib0056","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neo.2025.101153_bib0057","doi-asserted-by":"crossref","first-page":"e94993","DOI":"10.1371\/journal.pone.0094993","article-title":"Proteinase-activated receptor 1 (PAR1) regulates leukemic stem cell functions","volume":"9","author":"B\u00e4umer","year":"2014","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0058","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ajpath.2011.03.025","article-title":"Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer","volume":"179","author":"Cisowski","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.neo.2025.101153_bib0059","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jth.14616","article-title":"Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy","volume":"18","author":"Bliden","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.neo.2025.101153_bib0060","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.3390\/cells10123517","article-title":"Pleiotropic effects of the protease-activated receptor 1 (PAR1) inhibitor, Vorapaxar, on atherosclerosis and vascular inflammation","volume":"10","author":"Friebel","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neo.2025.101153_bib0061","first-page":"20","volume":"366","author":"Tricoci","year":"2012"},{"issue":"9850","key":"10.1016\/j.neo.2025.101153_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2\u00b0P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T09:14:11Z","timestamp":1744449251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":62,"alternative-id":["S1476558625000326"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101153","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101153"}}